CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
foretinib (formerly GSK1363089 or XL880)drug
Likely dose
foretinib (formerly GSK1363089 or XL880) 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00726323
NCT00726323Phase 2Completed
CompareCT.gov

A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma

GlaxoSmithKline·interventional·Posted Jul 31, 2008·Updated Dec 11, 2017

In Brief

A Phase 2 clinical trial evaluating foretinib (formerly GSK1363089 or XL880) for Carcinoma, Renal Cell. Completed, enrolled 74 participants across 12 sites.

Detailed Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 31, 2008
Enrollment StartJun 30, 2006
Primary CompletionAug 18, 2010
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.9 years ago

Interventions

foretinib (formerly GSK1363089 or XL880)drug

treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule